- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05164510
Value of ctDNA in the Treatment of Multiple Primary Cancers
December 7, 2021 updated by: Zhiguo Luo, MD, PhD, Fudan University
Exploratory Study on Gene Profiling of Circulating Tumor DNA(ctDNA) of Multiple Primary Cancers (MPC) and Its Value in Guidance of Clinical Choice of Drugs
This trial is a single-center, prospective, exploratory study.The objective is to study the peripheral blood circulating tumor DNA (CT-DNA) gene profile of patients with multiple primary tumors (MPC) and to evaluate the exploratory study for guiding drug selection.
Patients with multiple primary tumors who met the inclusion criteria and did not meet the exclusion criteria will be enrolled in this study.
CtDNA test will be used for CT-DNA gene profile study, and whether the test results can guide drug selection will be evaluated.The expected enrollment time is 12 months, and clinical observation is performed until disease progression and patient death.Additional CT-DNA tests will be performed as the disease progresses (2 cT-DNA tests in total).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This trial is a single-center, prospective, exploratory study.The objective is to study the peripheral blood CT-DNA gene profile of patients with multiple primary tumors and to evaluate the exploratory study for guiding drug selection.
Patients with multiple primary tumors who met the inclusion criteria and did not meet the exclusion criteria will be enrolled in this study.
CtDNA test will be used for CT-DNA gene profile study, and whether the test results can guide drug selection will be evaluated.The expected enrollment time is 12 months, and clinical observation is performed until disease progression and patient death.
Additional CT-DNA tests will be performed as the disease progresses (2 cT-DNA tests in total).
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Zhiguo Luo, MD
- Phone Number: 02164175590
- Email: luozhiguo88@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200032
- Fudan University Shanghai Cencer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients who were assessed to meet the diagnostic criteria for multiple primary tumors : each tumor had to be invasive histologically
- Each tumor has its own pathologic appearance
- Each tumor occurs in a different organ and must exclude metastasis or recurrence
- progress or failure after treatment on a standard regimen for related primary cancer
- regardless of gender, between 18 and 75
- The Eastern Cancer Collaboration Group (ECOG) scored 0 ~ 1 in physical condition (PS)
- has an estimated survival of more than three months;
- During 7 days (including 7 days) before screening, the laboratory test data were obtained: neutrophil count ≥1.5×109/L, platelet count ≥90×109/L, hemoglobin ≥90g/L (no transfusion within 14 days), serum total bilirubin ≤1.25 times normal upper limit (ULN);alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤ 2.5 x ULN (≤5x ULN in patients with liver metastasis);Serum creatinine ≤1.25 x ULN and creatinine clearance ≥60ml/min;
- Participating subjects (or their legal representative/guardian) had to sign an informed consent form saying they understood the study's objectives, understood the required procedures, and were willing to participate in the study.
Exclusion Criteria:
- have standard treatment for metastatic disease;
- Participants were given any experimental or antineoplastic drugs during the first four weeks of enrollment;
- Either symptomatic brain or meningeal metastasis (unless the patient is treated for something)At 6 months, imaging results were negative within 4 weeks prior to study entry and tumor-related clinical symptoms were stable at study entry);
- clinically active bleeding;
- Women who are pregnant or breastfeeding;Those who are fertile but do not take adequate contraceptive measures;
- addicted to alcohol or drugs;
- either major organ failure or other serious illness, including interstitial pneumonia, clinically relevant coronary disease, cardiovascular disease, or having myocardial infarction, congestive heart failure, unstable angina, pronounced pericardial effusion, or unstable arrhythmia in the first 6 months of the study;
- A history of severe neurological or mental illness;Severe infection;Active disseminated intravascular coagulation or other comorbidities that, in the investigator's judgment, seriously compromised the patient's safety or prevented the patient from completing the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ct-DNA test in MPC
treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
|
treatment according to ct-DNA results:For Patients with abnormal gene changes of corresponding targeted drugs are recommended to use corresponding targeted therapy or immunotherapy drugs;For Patients without abnormal gene changes of corresponding targeted drugs, Treatment of Physician's Choice (TPC) is recommended.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
number of patients with aberrant CT-DNA gene profile
Time Frame: 8 months
|
8 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
number of patients with drugable CT-DNA gene profile
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
December 1, 2021
Primary Completion (ANTICIPATED)
September 1, 2022
Study Completion (ANTICIPATED)
September 1, 2023
Study Registration Dates
First Submitted
September 7, 2021
First Submitted That Met QC Criteria
December 7, 2021
First Posted (ACTUAL)
December 20, 2021
Study Record Updates
Last Update Posted (ACTUAL)
December 20, 2021
Last Update Submitted That Met QC Criteria
December 7, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Fudan CMP-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Primary Cancers
-
Centre Leon BerardCompleted
-
The First Affiliated Hospital of Guangzhou Medical...UnknownMultiple Primary Lung CancersChina
-
Ruijin HospitalThe First Affiliated Hospital of Nanchang University; Second Affiliated Hospital... and other collaboratorsRecruitingMultiple Primary Lung CancersChina
-
University Hospital, RouenCompletedBreast Cancer | Colorectal Cancer | Ovarian Cancer | Pediatric Cancers | Multiple Primary Malignant TumoursFrance
-
RenJi HospitalUnknownMultiple Primary NeoplasmChina
-
Peking University People's HospitalGuangzhou Burning Rock Medical Examination Institute Co., Ltd.Not yet recruitingLung Cancer | Non Small Cell Lung Cancer | Multiple Primary Lung Cancers
-
Centre Leon BerardGlaxoSmithKlineRecruitingRecurrent Cancer | Second Cancer | Primary CancerFrance
-
National Cancer Institute (NCI)CompletedLymphomas | Leukemias | Multiple CancersUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
M.D. Anderson Cancer CenterRecruitingFatigue | Metastatic CancersUnited States
Clinical Trials on ct-DNA guided therapy
-
Jonsson Comprehensive Cancer CenterActive, not recruitingProstate AdenocarcinomaUnited States
-
Fudan UniversityRecruiting
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruitingDepressive Disorder | Depression | Cancer | Generalized Anxiety Disorder | Anxiety | Major Depressive DisorderUnited States
-
UNICANCERRecruiting
-
Chinese PLA General HospitalUnknown
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingLeukemia | Solid TumorFrance
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
CoreAalst BVRecruitingCoronary Artery DiseaseDenmark, United Kingdom, Belgium, Italy, Hungary
-
Chang ChenCompletedLung Neoplasm | Thoracic Surgery, Video-AssistedChina
-
Odense University HospitalNovo Nordisk A/S; AgeCare Academy of Geriatric Cancer ResearchCompleted